Advanced glycation end-product forming pathway (AGE pathway)

Advanced glycation end-product (AGE) forming pathways consist of a series of non-enzymatic chemical reactions, notably the Maillard reaction, where reducing sugars react with amino groups of proteins, lipids, and nucleic acids (Singh et al., 2014, PMID: 24399367). These reactions progress from reversible Schiff bases and Amadori products to irreversible, cross-linked AGEs, a process accelerated by hyperglycemia and oxidative stress (Ahmed, 2005, PMID: 15910630). The accumulation of AGEs in tissues leads to structural damage and triggers pro-inflammatory signaling through the Receptor for Advanced Glycation End-products (RAGE) (Vlassara & Uribarri, 2014, PMID: 24639280). Consequently, these pathways are central to the development of diabetic complications, cardiovascular diseases, and age-related neurodegeneration (Singh et al., 2014, PMID: 24399367). Pharmacological interventions aim to inhibit AGE formation using dicarbonyl scavengers like aminoguanidine or to break existing cross-links with agents like alagebrium (Thornalley, 2003, PMID: 12865317). While promising, the clinical utility of these drugs has been limited by safety issues and the challenge of effectively clearing long-lived AGE deposits (Thornalley, 2003, PMID: 12865317).

Other names

Maillard reactionNon-enzymatic glycationGlycation pathwaysBrowning reaction

Inhibition of reactive dicarbonyl intermediate formation, scavenging of alpha-dicarbonyls (e.g., methylglyoxal), breaking of established AGE cross-links, and activation of the glyoxalase system to detoxify precursors.